Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Raises Breakpoints In Final Labeling For Forest's Ceftaroline

Nov 08 2010

• By Cathy Dombrowski

Related Content

Financial Incentives Seen As A Path To Resurgence Of Antibiotics

Apr 26 2010

Antibiotic Development: FDA Says New Guidances Will Help, But Industry Questions Statistical Focus

Jun 28 2010

Forest Must Resolve Breakpoint Issues On Road To Ceftaroline Approval

Sep 13 2010

Theravance Gets To Market With Vibativ, But HAP Indication Could Be Pushed To 2010

Sep 14 2009

Drug Makers Face Higher Relabeling Burden For Antibacterial Resistance Info

Jul 07 2008

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window